Post-marketing surveillance of donepezil hydrochloride -Investigation of the clinical safety and effectiveness in patients with Alzheimer's Disease
Not Applicable
- Conditions
- Alzheimer's Disease
- Registration Number
- JPRN-jRCT1080221997
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Patients diagnosed as Alzheimer's Disease by DSM-IV.
Patients diagnosed as mild or moderate Alzheimer's Disease, applicable to FAST score 4 or 5.
Exclusion Criteria
Patients who used Aricept within 3 months prior to dosing.
Patients registered this survey before.
Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method